CleftGeneDB-Search

Gene: SNAI2

Basic information

Tag	Content
Uniprot ID	O43623; B2R6P6; Q53FC1;
Entrez ID	6591
Genbank protein ID	BAD97088.1; EAW86700.1; BAG35543.1; AAH15895.1; AAC34288.1; AAH14890.1; AAD55240.1;
Genbank nucleotide ID	NM_003068.4
Ensembl protein ID	ENSP00000020945
Ensembl nucleotide ID	ENSG00000019549
Gene name	Zinc finger protein SNAI2
Gene symbol	SNAI2
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Homology search
Reference
Functional description	Transcriptional repressor that modulates both activator-dependent and basal transcription. Involved in the generation and migration of neural crest cells. Plays a role in mediating RAF1-induced transcriptional repression of the TJ protein, occludin (OCLN) and subsequent oncogenic transformation of epithelial cells (By similarity). Represses BRCA2 expression by binding to its E2-box-containing silencer and recruiting CTBP1 and HDAC1 in breast cells. In epidermal keratinocytes, binds to the E-box in ITGA3 promoter and represses its transcription. Involved in the regulation of ITGB1 and ITGB4 expression and cell adhesion and proliferation in epidermal keratinocytes. Binds to E-box2 domain of BSG and activates its expression during TGFB1-induced epithelial-mesenchymal transition (EMT) in hepatocytes. Represses E-Cadherin/CDH1 transcription via E-box elements. Involved in osteoblast maturation. Binds to RUNX2 and SOC9 promoters and may act as a positive and negative transcription regulator, respectively, in osteoblasts. Binds to CXCL12 promoter via E-box regions in mesenchymal stem cells and osteoblasts. Plays an essential role in TWIST1-induced EMT and its ability to promote invasion and metastasis.
Sequence	MPRSFLVKKH FNASKKPNYS ELDTHTVIIS PYLYESYSMP VIPQPEILSS GAYSPITVWT 60 TAAPFHAQLP NGLSPLSGYS SSLGRVSPPP PSDTSSKDHS GSESPISDEE ERLQSKLSDP 120 HAIEAEKFQC NLCNKTYSTF SGLAKHKQLH CDAQSRKSFS CKYCDKEYVS LGALKMHIRT 180 HTLPCVCKIC GKAFSRPWLL QGHIRTHTGE KPFSCPHCNR AFADRSNLRA HLQTHSDVKK 240 YQCKNCSKTF SRMSLLHKHE ESGCCVAH 268

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

There is no related protein structure for this gene.

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Cleft type	Species	Evidence	Details
1:1 ortholog	SNAI2	520631	Q3MHQ4		Bos taurus	Prediction	More>>
1:1 ortholog	SNAI2		F1PTM6		Canis lupus familiaris	Prediction	More>>
1:1 ortholog	SNAI2	102178744	A0A452FYL7		Capra hircus	Prediction	More>>
1:1 ortholog	SNAI2	100050060	F6R5C0		Equus caballus	Prediction	More>>
1:1 ortholog	SNAI2	6591	O43623		Homo sapiens	Prediction	More>>
1:1 ortholog	Snai2	20583	P97469	CPO	Mus musculus	Publication	More>>
1:1 ortholog	SNAI2	464169	H2QW52		Pan troglodytes	Prediction	More>>
1:1 ortholog	SNAI2	102162332	A0A287A115		Sus scrofa	Prediction	More>>
1:1 ortholog	SNAI2	100346095	G1T2X3		Oryctolagus cuniculus	Prediction	More>>
1:1 ortholog	Snai2	25554	O08954		Rattus norvegicus	Prediction	More>>
1:1 ortholog	snai2	494038	Q5PQY5		Danio rerio	Prediction	More>>

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
COSM2718144	p.Arg3Pro	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48921258C>G	NCI-TCGA Cosmic
rs546348236	p.Ser4Phe	missense variant	-	NC_000008.11:g.48921255G>A	1000Genomes
rs769859276	p.Val7Ile	missense variant	-	NC_000008.11:g.48921247C>T	ExAC,gnomAD
COSM1100353	p.Lys8Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48921242C>A	NCI-TCGA Cosmic
COSM3900502	p.Lys9Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48921240T>C	NCI-TCGA Cosmic
rs763952937	p.Asn12Asp	missense variant	-	NC_000008.11:g.48921232T>C	NCI-TCGA
rs763952937	p.Asn12Asp	missense variant	-	NC_000008.11:g.48921232T>C	ExAC,TOPMed,gnomAD
rs781159401	p.Asn12Ser	missense variant	-	NC_000008.11:g.48921231T>C	ExAC,TOPMed,gnomAD
rs754767647	p.Asn12Lys	missense variant	-	NC_000008.11:g.48921230G>C	ExAC,gnomAD
rs149755644	p.Ala13Val	missense variant	-	NC_000008.11:g.48921228G>A	ESP,gnomAD
rs1215764853	p.Asn18Thr	missense variant	-	NC_000008.11:g.48921213T>G	gnomAD
NCI-TCGA novel	p.Tyr19Ter	stop gained	-	NC_000008.11:g.48921209G>C	NCI-TCGA
rs560825840	p.Glu21Lys	missense variant	-	NC_000008.11:g.48921205C>T	1000Genomes,ExAC,gnomAD
rs1277074927	p.His25Gln	missense variant	-	NC_000008.11:g.48921191A>C	TOPMed,gnomAD
rs1415310272	p.Thr26Ala	missense variant	-	NC_000008.11:g.48921190T>C	gnomAD
COSM1100352	p.Ile28Ser	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48920438A>C	NCI-TCGA Cosmic
COSM277403	p.Ser30Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48920432G>A	NCI-TCGA Cosmic
COSM3900501	p.Pro31Ser	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48920430G>A	NCI-TCGA Cosmic
rs1207656642	p.Pro31Leu	missense variant	-	NC_000008.11:g.48920429G>A	TOPMed
rs1010772676	p.Tyr32Asn	missense variant	-	NC_000008.11:g.48920427A>T	TOPMed
rs748128814	p.Leu33Val	missense variant	-	NC_000008.11:g.48920424G>C	ExAC,gnomAD
rs748128814	p.Leu33Val	missense variant	-	NC_000008.11:g.48920424G>C	NCI-TCGA
rs768624071	p.Tyr34Cys	missense variant	-	NC_000008.11:g.48920420T>C	ExAC,TOPMed,gnomAD
rs768624071	p.Tyr34Ser	missense variant	-	NC_000008.11:g.48920420T>G	ExAC,TOPMed,gnomAD
rs746846227	p.Glu35Asp	missense variant	-	NC_000008.11:g.48920416C>G	ExAC,gnomAD
NCI-TCGA novel	p.Tyr37Ter	stop gained	-	NC_000008.11:g.48920410G>T	NCI-TCGA
rs779831481	p.Ser38Cys	missense variant	-	NC_000008.11:g.48920408G>C	ExAC,gnomAD
COSM3900500	p.Met39Thr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48920405A>G	NCI-TCGA Cosmic
rs891783277	p.Pro40Ser	missense variant	-	NC_000008.11:g.48920403G>A	TOPMed
rs1175916832	p.Pro40Leu	missense variant	-	NC_000008.11:g.48920402G>A	gnomAD
rs891783277	p.Pro40Ser	missense variant	-	NC_000008.11:g.48920403G>A	NCI-TCGA
COSM1100351	p.Val41Ala	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48920399A>G	NCI-TCGA Cosmic
rs1213724397	p.Ile42Lys	missense variant	-	NC_000008.11:g.48920396A>T	gnomAD
NCI-TCGA novel	p.Pro43Ser	missense variant	-	NC_000008.11:g.48920394G>A	NCI-TCGA
COSM751319	p.Pro43Gln	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48920393G>T	NCI-TCGA Cosmic
rs757995996	p.Pro43Leu	missense variant	-	NC_000008.11:g.48920393G>A	ExAC,gnomAD
rs1469445385	p.Pro43Thr	missense variant	-	NC_000008.11:g.48920394G>T	gnomAD
RCV000299485	p.Gln44Lys	missense variant	Partial albinism (PBT)	NC_000008.11:g.48920391G>T	ClinVar
RCV000400781	p.Gln44Lys	missense variant	Waardenburg syndrome	NC_000008.11:g.48920391G>T	ClinVar
rs886062986	p.Gln44Lys	missense variant	-	NC_000008.11:g.48920391G>T	gnomAD
rs1277260069	p.Ile47Ser	missense variant	-	NC_000008.11:g.48920381A>C	gnomAD
rs750024548	p.Leu48Phe	missense variant	-	NC_000008.11:g.48920379G>A	ExAC
rs79619080	p.Ser49Asn	missense variant	-	NC_000008.11:g.48920375C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs756797339	p.Ser50Leu	missense variant	-	NC_000008.11:g.48920372G>A	ExAC,gnomAD
NCI-TCGA novel	p.Gly51Glu	missense variant	-	NC_000008.11:g.48920369C>T	NCI-TCGA
COSM3900499	p.Ala52Glu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48920366G>T	NCI-TCGA Cosmic
rs753326846	p.Ala52Thr	missense variant	-	NC_000008.11:g.48920367C>T	ExAC,gnomAD
rs1450132140	p.Pro55Ala	missense variant	-	NC_000008.11:g.48920358G>C	TOPMed,gnomAD
rs1443142509	p.Ile56Asn	missense variant	-	NC_000008.11:g.48920354A>T	gnomAD
rs746436655	p.Thr57Ser	missense variant	-	NC_000008.11:g.48920352T>A	ExAC,TOPMed,gnomAD
rs1438797146	p.Pro64Arg	missense variant	-	NC_000008.11:g.48920330G>C	TOPMed
COSM6180839	p.Ala67Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48920321G>T	NCI-TCGA Cosmic
rs367909953	p.Ala67Ser	missense variant	-	NC_000008.11:g.48920322C>A	ESP,ExAC,TOPMed,gnomAD
rs367909953	p.Ala67Thr	missense variant	-	NC_000008.11:g.48920322C>T	ESP,ExAC,TOPMed,gnomAD
rs1387214058	p.Ala67Val	missense variant	-	NC_000008.11:g.48920321G>A	TOPMed
NCI-TCGA novel	p.Gln68Arg	missense variant	-	NC_000008.11:g.48920318T>C	NCI-TCGA
NCI-TCGA novel	p.Gln68Ter	stop gained	-	NC_000008.11:g.48920320_48920321insTTTCAGTGCAATTTAT	NCI-TCGA
rs1158057325	p.Leu69Pro	missense variant	-	NC_000008.11:g.48920315A>G	gnomAD
NCI-TCGA novel	p.Asn71Lys	missense variant	-	NC_000008.11:g.48920308A>T	NCI-TCGA
rs1455349039	p.Asn71Ser	missense variant	-	NC_000008.11:g.48920309T>C	gnomAD
rs530556235	p.Asn71Asp	missense variant	-	NC_000008.11:g.48920310T>C	1000Genomes
rs766684538	p.Gly72Cys	missense variant	-	NC_000008.11:g.48920307C>A	ExAC,gnomAD
rs763181346	p.Leu73Phe	missense variant	-	NC_000008.11:g.48920304G>A	ExAC,gnomAD
rs199497690	p.Leu76Phe	missense variant	-	NC_000008.11:g.48920295G>A	gnomAD
rs372039867	p.Ser77Phe	missense variant	-	NC_000008.11:g.48920291G>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs544948095	p.Ser77Pro	missense variant	-	NC_000008.11:g.48920292A>G	1000Genomes,ExAC,TOPMed,gnomAD
rs372039867	p.Ser77Cys	missense variant	-	NC_000008.11:g.48920291G>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Gly78Ter	stop gained	-	NC_000008.11:g.48920289C>A	NCI-TCGA
rs915887115	p.Gly78Arg	missense variant	-	NC_000008.11:g.48920289C>T	TOPMed
rs1236743543	p.Gly78Val	missense variant	-	NC_000008.11:g.48920288C>A	gnomAD
rs915887115	p.Gly78Arg	missense variant	-	NC_000008.11:g.48920289C>T	NCI-TCGA Cosmic
rs1300597470	p.Ser80Thr	missense variant	-	NC_000008.11:g.48920283A>T	TOPMed,gnomAD
rs1364642218	p.Ser82Cys	missense variant	-	NC_000008.11:g.48920276G>C	gnomAD
rs1287664441	p.Gly84Glu	missense variant	-	NC_000008.11:g.48920270C>T	gnomAD
rs1175977420	p.Arg85Gln	missense variant	-	NC_000008.11:g.48920267C>T	gnomAD
rs146310523	p.Arg85Gly	missense variant	-	NC_000008.11:g.48920268G>C	ESP,ExAC,TOPMed,gnomAD
RCV000398284	p.Val86Ala	missense variant	Waardenburg syndrome	NC_000008.11:g.48920264A>G	ClinVar
RCV000350118	p.Val86Ala	missense variant	Partial albinism (PBT)	NC_000008.11:g.48920264A>G	ClinVar
rs186986959	p.Val86Ala	missense variant	-	NC_000008.11:g.48920264A>G	1000Genomes,ExAC,TOPMed,gnomAD
rs756592742	p.Val86Met	missense variant	-	NC_000008.11:g.48920265C>T	ExAC,gnomAD
rs186986959	p.Val86Gly	missense variant	-	NC_000008.11:g.48920264A>C	1000Genomes,ExAC,TOPMed,gnomAD
rs767804680	p.Ser87Gly	missense variant	-	NC_000008.11:g.48920262T>C	ExAC,gnomAD
rs755435590	p.Ser87Arg	missense variant	-	NC_000008.11:g.48920260A>C	ExAC,TOPMed,gnomAD
rs751957538	p.Pro88Leu	missense variant	-	NC_000008.11:g.48920258G>A	ExAC,gnomAD
rs1487949599	p.Pro89Thr	missense variant	-	NC_000008.11:g.48920256G>T	gnomAD
rs763201300	p.Pro90Ser	missense variant	-	NC_000008.11:g.48920253G>A	ExAC,gnomAD
rs928687637	p.Pro91Leu	missense variant	-	NC_000008.11:g.48920249G>A	TOPMed
NCI-TCGA novel	p.Lys97Met	missense variant	-	NC_000008.11:g.48920231T>A	NCI-TCGA
rs765308302	p.Asp98Asn	missense variant	-	NC_000008.11:g.48920229C>T	ExAC,gnomAD
COSM751321	p.Asp98Tyr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48920229C>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Ser100Arg	missense variant	-	NC_000008.11:g.48920221A>C	NCI-TCGA
rs760557285	p.Ile106Val	missense variant	-	NC_000008.11:g.48920205T>C	ExAC,gnomAD
NCI-TCGA novel	p.Glu110Lys	missense variant	-	NC_000008.11:g.48920193C>T	NCI-TCGA
COSM486504	p.Glu110Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48920192T>A	NCI-TCGA Cosmic
rs1408977509	p.Glu110Ala	missense variant	-	NC_000008.11:g.48920192T>G	TOPMed
rs1293589280	p.Glu111Gln	missense variant	-	NC_000008.11:g.48920190C>G	TOPMed,gnomAD
rs1399921076	p.Glu111Gly	missense variant	-	NC_000008.11:g.48920189T>C	gnomAD
rs1356727405	p.Arg112Lys	missense variant	-	NC_000008.11:g.48920186C>T	gnomAD
rs775535419	p.Arg112Ser	missense variant	-	NC_000008.11:g.48920185T>A	ExAC,gnomAD
rs200288712	p.Gln114Pro	missense variant	-	NC_000008.11:g.48920180T>G	ESP,ExAC,TOPMed,gnomAD
rs745724072	p.Ser115Phe	missense variant	-	NC_000008.11:g.48920177G>A	ExAC,gnomAD
rs774130913	p.Lys116Arg	missense variant	-	NC_000008.11:g.48920174T>C	ExAC,gnomAD
rs1167988676	p.Leu117Pro	missense variant	-	NC_000008.11:g.48920171A>G	gnomAD
COSM605886	p.Leu117Ile	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48920172G>T	NCI-TCGA Cosmic
rs1021817915	p.Leu117Phe	missense variant	-	NC_000008.11:g.48920172G>A	TOPMed,gnomAD
NCI-TCGA novel	p.Asp119Asn	missense variant	-	NC_000008.11:g.48920166C>T	NCI-TCGA
rs748917911	p.Asp119Glu	missense variant	-	NC_000008.11:g.48920164G>T	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Pro120Leu	missense variant	-	NC_000008.11:g.48920162G>A	NCI-TCGA
rs777170757	p.Pro120Thr	missense variant	-	NC_000008.11:g.48920163G>T	ExAC,TOPMed,gnomAD
rs777170757	p.Pro120Ser	missense variant	-	NC_000008.11:g.48920163G>A	ExAC,TOPMed,gnomAD
rs907510990	p.Ala122Thr	missense variant	-	NC_000008.11:g.48920157C>T	TOPMed
rs181954619	p.Ala122Gly	missense variant	-	NC_000008.11:g.48920156G>C	1000Genomes,ExAC,TOPMed,gnomAD
rs181954619	p.Ala122Val	missense variant	-	NC_000008.11:g.48920156G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs747582227	p.Ile123Val	missense variant	-	NC_000008.11:g.48920154T>C	ExAC,gnomAD
rs781778604	p.Ile123Thr	missense variant	-	NC_000008.11:g.48920153A>G	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Ala125Thr	missense variant	-	NC_000008.11:g.48920148C>T	NCI-TCGA
rs1287658107	p.Lys127Gln	missense variant	-	NC_000008.11:g.48920142T>G	gnomAD
rs1218100937	p.Cys130Arg	missense variant	-	NC_000008.11:g.48920133A>G	gnomAD
rs1336032756	p.Cys130Trp	missense variant	-	NC_000008.11:g.48920131G>C	gnomAD
rs1472034350	p.Asn131Ser	missense variant	-	NC_000008.11:g.48920129T>C	TOPMed
rs1243515213	p.Asn131Tyr	missense variant	-	NC_000008.11:g.48920130T>A	gnomAD
NCI-TCGA novel	p.Cys133Ter	stop gained	-	NC_000008.11:g.48920122G>T	NCI-TCGA
COSM72747	p.Asn134Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48920121T>C	NCI-TCGA Cosmic
rs200799419	p.Asn134Ser	missense variant	-	NC_000008.11:g.48920120T>C	1000Genomes,ExAC,TOPMed,gnomAD
rs200799419	p.Asn134Ser	missense variant	-	NC_000008.11:g.48920120T>C	NCI-TCGA,NCI-TCGA Cosmic
rs750615415	p.Thr136Ala	missense variant	-	NC_000008.11:g.48920115T>C	ExAC,TOPMed,gnomAD
COSM258068	p.Ser141Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48920099G>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Gly142Trp	missense variant	-	NC_000008.11:g.48920097C>A	NCI-TCGA
NCI-TCGA novel	p.Gly142Val	missense variant	-	NC_000008.11:g.48920096C>A	NCI-TCGA
rs201280051	p.Leu143Met	missense variant	-	NC_000008.11:g.48920094G>T	1000Genomes,ExAC,gnomAD
rs753851004	p.Ala144Thr	missense variant	-	NC_000008.11:g.48920091C>T	ExAC,gnomAD
rs1450198644	p.Ala144Gly	missense variant	-	NC_000008.11:g.48920090G>C	gnomAD
rs1324596275	p.Lys145Glu	missense variant	-	NC_000008.11:g.48920088T>C	gnomAD
rs759405037	p.His146Arg	missense variant	-	NC_000008.11:g.48920084T>C	ExAC,TOPMed,gnomAD
rs774149293	p.Leu149Val	missense variant	-	NC_000008.11:g.48920076G>C	ExAC,gnomAD
COSM6113268	p.Cys151Trp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48920068G>C	NCI-TCGA Cosmic
NCI-TCGA novel	p.Asp152Asn	missense variant	-	NC_000008.11:g.48920067C>T	NCI-TCGA
rs762545404	p.Ala153Val	missense variant	-	NC_000008.11:g.48920063G>A	ExAC,gnomAD
rs770664185	p.Ala153Thr	missense variant	-	NC_000008.11:g.48920064C>T	ExAC,gnomAD
rs1367659132	p.Gln154Arg	missense variant	-	NC_000008.11:g.48920060T>C	gnomAD
rs1182336073	p.Ser155Ala	missense variant	-	NC_000008.11:g.48920058A>C	gnomAD
rs772959139	p.Arg156Gly	missense variant	-	NC_000008.11:g.48920055T>C	ExAC,gnomAD
rs769311446	p.Ser158Tyr	missense variant	-	NC_000008.11:g.48920048G>T	NCI-TCGA
rs769311446	p.Ser158Tyr	missense variant	-	NC_000008.11:g.48920048G>T	ExAC,gnomAD
rs769311446	p.Ser158Cys	missense variant	-	NC_000008.11:g.48920048G>C	ExAC,gnomAD
rs747758720	p.Phe159Cys	missense variant	-	NC_000008.11:g.48920045A>C	ExAC,gnomAD
rs1445609110	p.Ser160Arg	missense variant	-	NC_000008.11:g.48920043T>G	TOPMed
rs780781747	p.Ser160Thr	missense variant	-	NC_000008.11:g.48920042C>G	ExAC,gnomAD
NCI-TCGA novel	p.Cys161Tyr	missense variant	-	NC_000008.11:g.48920039C>T	NCI-TCGA
rs374589338	p.Asp165Gly	missense variant	-	NC_000008.11:g.48920027T>C	ESP
NCI-TCGA novel	p.Lys166Asn	missense variant	-	NC_000008.11:g.48920023C>A	NCI-TCGA
COSM2718130	p.Ala173Thr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48920004C>T	NCI-TCGA Cosmic
rs769299661	p.Ala173Gly	missense variant	-	NC_000008.11:g.48920003G>C	ExAC,gnomAD
COSM1100349	p.Lys175Glu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48919998T>C	NCI-TCGA Cosmic
rs780596140	p.Met176Thr	missense variant	-	NC_000008.11:g.48919994A>G	ExAC,gnomAD
NCI-TCGA novel	p.Arg179Trp	missense variant	-	NC_000008.11:g.48919986G>A	NCI-TCGA
rs758835778	p.Arg179Gln	missense variant	-	NC_000008.11:g.48919985C>T	ExAC,gnomAD
NCI-TCGA novel	p.Thr180CysPheSerTerUnkUnk	frameshift	-	NC_000008.11:g.48919967_48919983CAAGGTAATGTGTGGGT>-	NCI-TCGA
rs1306669436	p.Cys187Tyr	missense variant	-	NC_000008.11:g.48919961C>T	gnomAD
NCI-TCGA novel	p.Lys188Asn	missense variant	-	NC_000008.11:g.48919957C>G	NCI-TCGA
rs750730056	p.Lys188Asn	missense variant	-	NC_000008.11:g.48919957C>A	ExAC,gnomAD
rs779251454	p.Ile189Leu	missense variant	-	NC_000008.11:g.48919956T>G	ExAC,gnomAD
rs757418816	p.Gly191Ser	missense variant	-	NC_000008.11:g.48919950C>T	ExAC,gnomAD
NCI-TCGA novel	p.Ala193Glu	missense variant	-	NC_000008.11:g.48919943G>T	NCI-TCGA
NCI-TCGA novel	p.Pro197Leu	missense variant	-	NC_000008.11:g.48919931G>A	NCI-TCGA
NCI-TCGA novel	p.Leu199Val	missense variant	-	NC_000008.11:g.48919926A>C	NCI-TCGA
rs1424430619	p.Gln201Arg	missense variant	-	NC_000008.11:g.48919919T>C	gnomAD
COSM1226930	p.Arg205Ile	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48919907C>A	NCI-TCGA Cosmic
COSM751323	p.Arg205Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48919907C>T	NCI-TCGA Cosmic
rs1229742703	p.Thr208Met	missense variant	-	NC_000008.11:g.48919898G>A	TOPMed
NCI-TCGA novel	p.His217Tyr	missense variant	-	NC_000008.11:g.48918965G>A	NCI-TCGA
NCI-TCGA novel	p.His217Asn	missense variant	-	NC_000008.11:g.48918965G>T	NCI-TCGA
COSM3413047	p.Asn219Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48918957G>T	NCI-TCGA Cosmic
NCI-TCGA novel	p.Phe222LeuPheSerTerUnk	frameshift	-	NC_000008.11:g.48918948A>-	NCI-TCGA
rs141976823	p.Arg225Lys	missense variant	-	NC_000008.11:g.48918940C>T	ESP,ExAC
COSM1100346	p.Leu228Met	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48918932G>T	NCI-TCGA Cosmic
NCI-TCGA novel	p.Gln233His	missense variant	-	NC_000008.11:g.48918915C>A	NCI-TCGA
NCI-TCGA novel	p.Asp237Asn	missense variant	-	NC_000008.11:g.48918905C>T	NCI-TCGA
rs1250018038	p.Val238Ala	missense variant	-	NC_000008.11:g.48918901A>G	TOPMed
COSM3649499	p.Lys239Glu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48918899T>C	NCI-TCGA Cosmic
rs1270319958	p.Tyr241Ter	stop gained	-	NC_000008.11:g.48918891G>T	gnomAD
rs750242653	p.Gln242Pro	missense variant	-	NC_000008.11:g.48918889T>G	ExAC,TOPMed,gnomAD
rs750242653	p.Gln242Arg	missense variant	-	NC_000008.11:g.48918889T>C	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Asn245ThrPheSerTerUnkUnk	frameshift	-	NC_000008.11:g.48918880T>-	NCI-TCGA
rs138847615	p.Asn245His	missense variant	-	NC_000008.11:g.48918881T>G	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Cys246Ter	stop gained	-	NC_000008.11:g.48918876G>T	NCI-TCGA
NCI-TCGA novel	p.Ser247Phe	missense variant	-	NC_000008.11:g.48918874G>A	NCI-TCGA
rs376627182	p.Ser247Cys	missense variant	-	NC_000008.11:g.48918874G>C	ESP,TOPMed
COSM3900496	p.Thr249Pro	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.48918869T>G	NCI-TCGA Cosmic
NCI-TCGA novel	p.Phe250Leu	missense variant	-	NC_000008.11:g.48918864G>T	NCI-TCGA
rs1361071168	p.Met253Leu	missense variant	-	NC_000008.11:g.48918857T>G	gnomAD
rs763814813	p.Ser254Thr	missense variant	-	NC_000008.11:g.48918854A>T	ExAC,TOPMed,gnomAD
rs1414167926	p.Leu255Val	missense variant	-	NC_000008.11:g.48918851G>C	gnomAD
rs1054521876	p.His257Arg	missense variant	-	NC_000008.11:g.48918844T>C	TOPMed
rs1169791779	p.Lys258Arg	missense variant	-	NC_000008.11:g.48918841T>C	gnomAD
rs1477087613	p.Lys258Asn	missense variant	-	NC_000008.11:g.48918840T>A	gnomAD
rs1486877958	p.Glu261Asp	missense variant	-	NC_000008.11:g.48918831T>A	gnomAD
rs932078973	p.Glu261Gly	missense variant	-	NC_000008.11:g.48918832T>C	TOPMed,gnomAD
rs1011653120	p.Gly263Ser	missense variant	-	NC_000008.11:g.48918827C>T	gnomAD
rs772639292	p.Cys265Tyr	missense variant	-	NC_000008.11:g.48918820C>T	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Val266Ala	missense variant	-	NC_000008.11:g.48918817A>G	NCI-TCGA
rs1304900927	p.HisTer268GlnUnk	stop lost	-	NC_000008.11:g.48918809_48918810del	TOPMed
rs1273093098	p.His268Arg	missense variant	-	NC_000008.11:g.48918811T>C	gnomAD

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0001418	Adenocarcinoma	group	BEFREE
C0003850	Arteriosclerosis	disease	BEFREE
C0003873	Rheumatoid Arthritis	disease	BEFREE
C0004153	Atherosclerosis	disease	BEFREE
C0006142	Malignant neoplasm of breast	disease	BEFREE;CTD_human
C0006826	Malignant Neoplasms	group	BEFREE;HPO
C0007102	Malignant tumor of colon	disease	BEFREE
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE
C0007133	Carcinoma, Papillary	disease	BEFREE;LHGDN
C0007134	Renal Cell Carcinoma	disease	BEFREE
C0007137	Squamous cell carcinoma	disease	BEFREE
C0008487	Chordoma	disease	BEFREE
C0009402	Colorectal Carcinoma	disease	BEFREE
C0009404	Colorectal Neoplasms	group	BEFREE
C0014859	Esophageal Neoplasms	group	CTD_human
C0017636	Glioblastoma	disease	BEFREE
C0017638	Glioma	disease	BEFREE
C0018784	Sensorineural Hearing Loss (disorder)	disease	HPO
C0019569	Hirschsprung Disease	disease	HPO
C0021367	Mammary Ductal Carcinoma	disease	BEFREE
C0023269	leiomyosarcoma	disease	BEFREE
C0024623	Malignant neoplasm of stomach	disease	BEFREE
C0025160	Megacolon	phenotype	HPO
C0025202	melanoma	disease	BEFREE
C0025500	Mesothelioma	disease	LHGDN
C0027626	Neoplasm Invasiveness	phenotype	CTD_human
C0027627	Neoplasm Metastasis	phenotype	BEFREE;CTD_human;LHGDN
C0027651	Neoplasms	group	BEFREE;HPO
C0027794	Neural Tube Defects	group	BEFREE
C0027819	Neuroblastoma	group	BEFREE
C0028754	Obesity	disease	BEFREE
C0029463	Osteosarcoma	disease	BEFREE
C0029925	Ovarian Carcinoma	disease	BEFREE
C0031511	Pheochromocytoma	disease	BEFREE
C0033578	Prostatic Neoplasms	group	LHGDN
C0036421	Systemic Scleroderma	disease	BEFREE
C0080024	Piebaldism	disease	BEFREE;CTD_human;HPO;ORPHANET
C0085786	Hamman-Rich syndrome	disease	BEFREE
C0153676	Secondary malignant neoplasm of lung	disease	BEFREE
C0153690	Secondary malignant neoplasm of bone	disease	BEFREE
C0162835	Hypopigmentation disorder	group	BEFREE
C0178874	Tumor Progression	phenotype	BEFREE
C0206660	Germinoma	disease	BEFREE
C0206698	Cholangiocarcinoma	disease	BEFREE
C0238198	Gastrointestinal Stromal Tumors	group	BEFREE
C0238463	Papillary thyroid carcinoma	disease	CTD_human
C0242379	Malignant neoplasm of lung	disease	BEFREE
C0263498	Premature canities	phenotype	HPO
C0266589	Congenital ear anomaly NOS (disorder)	group	HPO
C0278488	Carcinoma breast stage IV	disease	BEFREE
C0280630	Uterine Carcinosarcoma	disease	BEFREE
C0332573	Macule	phenotype	HPO
C0344312	White forelock	phenotype	HPO
C0346429	Multiple malignancy	phenotype	BEFREE
C0349566	Squamous cell carcinoma of tongue	disease	BEFREE
C0376358	Malignant neoplasm of prostate	disease	BEFREE
C0423113	Telecanthus	phenotype	HPO
C0423318	Heterochromia iridis	phenotype	HPO
C0521158	Recurrent tumor	phenotype	BEFREE
C0546837	Malignant neoplasm of esophagus	disease	CTD_human
C0549473	Thyroid carcinoma	disease	BEFREE
C0585442	Osteosarcoma of bone	disease	BEFREE
C0587248	Costello syndrome (disorder)	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0598935	Tumor Initiation	phenotype	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0677886	Epithelial ovarian cancer	disease	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE;CTD_human
C0684249	Carcinoma of lung	disease	BEFREE
C0686619	Secondary malignant neoplasm of lymph node	disease	BEFREE
C0699790	Colon Carcinoma	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C0699893	Skin carcinoma	disease	BEFREE
C0700095	Central neuroblastoma	disease	BEFREE
C0936223	Metastatic Prostate Carcinoma	disease	BEFREE
C1140680	Malignant neoplasm of ovary	disease	BEFREE
C1168401	Squamous cell carcinoma of the head and neck	disease	BEFREE
C1257931	Mammary Neoplasms, Human	group	CTD_human
C1282496	Metastasis from malignant tumor of prostate	disease	BEFREE
C1306459	Primary malignant neoplasm	group	BEFREE
C1306460	Primary malignant neoplasm of lung	disease	BEFREE
C1368683	Epithelioma	disease	BEFREE
C1458155	Mammary Neoplasms	group	BEFREE;CTD_human;LHGDN
C1527249	Colorectal Cancer	disease	BEFREE
C1527349	Ductal Breast Carcinoma	disease	BEFREE
C1559154	Rash and Dermatitis Adverse Event Associated with Chemoradiation	disease	BEFREE
C1704376	Uterine Corpus Carcinosarcoma	disease	BEFREE
C1800706	Idiopathic Pulmonary Fibrosis	disease	BEFREE
C1836735	hypopigmented skin patch	phenotype	HPO
C1836736	White eyelashes	phenotype	HPO
C1836737	White eyebrow	phenotype	HPO
C1837203	WAARDENBURG SYNDROME, TYPE IID	disease	CTD_human;MGD
C1865866	Congenital sensorineural hearing loss	disease	HPO
C2239176	Liver carcinoma	disease	BEFREE
C2700265	Waardenburg Syndrome Type 2	disease	BEFREE;ORPHANET
C3501843	Non-medullary thyroid carcinoma	disease	CTD_human
C3501844	Familial Nonmedullary Thyroid Cancer	disease	CTD_human
C3539878	Triple Negative Breast Neoplasms	disease	BEFREE
C3642345	Luminal A Breast Carcinoma	disease	BEFREE
C3642347	Basal-Like Breast Carcinoma	disease	BEFREE
C3888391	Nonnuclear polymorphic congenital cataract	disease	BEFREE
C4024848	Absent pigmentation of the ventral chest	disease	HPO
C4280578	Grey eyelashes	phenotype	HPO
C4280579	Grey eyebrow	phenotype	HPO
C4280580	Blonde eyebrow	phenotype	HPO
C4282132	Malignancy	phenotype	BEFREE

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0000977	RNA polymerase II regulatory region sequence-specific DNA binding	IDA
GO:0001227	DNA-binding transcription repressor activity, RNA polymerase II-specific	IDA
GO:0003677	DNA binding	IBA
GO:0003682	chromatin binding	IEA
GO:0003700	DNA-binding transcription factor activity	IBA
GO:0005515	protein binding	IPI
GO:0043565	sequence-specific DNA binding	IDA
GO:0046872	metal ion binding	IEA
GO:0070888	E-box binding	IDA

GO:Biological Process

GO ID	GO Term	Evidence
GO:0000122	negative regulation of transcription by RNA polymerase II	IDA
GO:0000122	negative regulation of transcription by RNA polymerase II	IMP
GO:0001649	osteoblast differentiation	IEP
GO:0001837	epithelial to mesenchymal transition	IMP
GO:0003180	aortic valve morphogenesis	TAS
GO:0003198	epithelial to mesenchymal transition involved in endocardial cushion formation	ISS
GO:0003198	epithelial to mesenchymal transition involved in endocardial cushion formation	TAS
GO:0003273	cell migration involved in endocardial cushion formation	ISS
GO:0006355	regulation of transcription, DNA-templated	IBA
GO:0006933	negative regulation of cell adhesion involved in substrate-bound cell migration	IEA
GO:0007219	Notch signaling pathway	IMP
GO:0007605	sensory perception of sound	IMP
GO:0010839	negative regulation of keratinocyte proliferation	IDA
GO:0010957	negative regulation of vitamin D biosynthetic process	IDA
GO:0014032	neural crest cell development	IMP
GO:0030335	positive regulation of cell migration	IMP
GO:0032331	negative regulation of chondrocyte differentiation	IMP
GO:0032642	regulation of chemokine production	IMP
GO:0033629	negative regulation of cell adhesion mediated by integrin	IC
GO:0035066	positive regulation of histone acetylation	IEA
GO:0035921	desmosome disassembly	IMP
GO:0043473	pigmentation	IMP
GO:0043518	negative regulation of DNA damage response, signal transduction by p53 class mediator	IMP
GO:0045600	positive regulation of fat cell differentiation	IEA
GO:0045667	regulation of osteoblast differentiation	IMP
GO:0050872	white fat cell differentiation	IEA
GO:0060021	roof of mouth development	IEA
GO:0060429	epithelium development	ISS
GO:0060536	cartilage morphogenesis	IEA
GO:0060693	regulation of branching involved in salivary gland morphogenesis	IEA
GO:0061314	Notch signaling involved in heart development	TAS
GO:0070563	negative regulation of vitamin D receptor signaling pathway	IDA
GO:0071364	cellular response to epidermal growth factor stimulus	IDA
GO:0071479	cellular response to ionizing radiation	IEA
GO:0090090	negative regulation of canonical Wnt signaling pathway	IDA
GO:0090090	negative regulation of canonical Wnt signaling pathway	IMP
GO:1900387	negative regulation of cell-cell adhesion by negative regulation of transcription from RNA polymerase II promoter	IMP
GO:1902230	negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage	IMP
GO:2000647	negative regulation of stem cell proliferation	IEA
GO:2000810	regulation of bicellular tight junction assembly	IMP
GO:2000811	negative regulation of anoikis	IMP
GO:2001240	negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	ISS

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0000790	nuclear chromatin	IDA
GO:0005634	nucleus	IDA
GO:0005634	nucleus	IBA
GO:0005654	nucleoplasm	TAS
GO:0005737	cytoplasm	IEA

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-1257604	PIP3 activates AKT signaling	IEA
R-HSA-1257604	PIP3 activates AKT signaling	TAS
R-HSA-162582	Signal Transduction	IEA
R-HSA-162582	Signal Transduction	TAS
R-HSA-6807070	PTEN Regulation	IEA
R-HSA-6807070	PTEN Regulation	TAS
R-HSA-8943724	Regulation of PTEN gene transcription	IEA
R-HSA-8943724	Regulation of PTEN gene transcription	TAS
R-HSA-9006925	Intracellular signaling by second messengers	IEA
R-HSA-9006925	Intracellular signaling by second messengers	TAS

Drugs and compounds information

ID	Drug Name	Action	PubMed
C031763	1,3-butadiene	1,3-butadiene results in decreased expression of SNAI2 mRNA	29038090
D020001	1-Butanol	[[Gasoline co-treated with 1-Butanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SNAI2 mRNA	29432896
D015056	1-Methyl-3-isobutylxanthine	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SNAI2 mRNA	28628672
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium results in increased expression of SNAI2 mRNA	24810058
C051246	1-methylanthracene	[1-methylanthracene co-treated with fluoranthene] results in increased expression of SNAI2 mRNA	28329830
C548651	2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester	2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in decreased expression of SNAI2 mRNA	19933214
C525921	2-(4-(biphenyl-4-sulfonyl)-piperazin-1-yl)-6,7-dipropoxyquinazolin-4-yl-amine	2-(4-(biphenyl-4-sulfonyl)-piperazin-1-yl)-6,7-dipropoxyquinazolin-4-yl-amine results in decreased expression of SNAI2 mRNA	29108245
C525921	2-(4-(biphenyl-4-sulfonyl)-piperazin-1-yl)-6,7-dipropoxyquinazolin-4-yl-amine	TLN1 protein inhibits the reaction [2-(4-(biphenyl-4-sulfonyl)-piperazin-1-yl)-6,7-dipropoxyquinazolin-4-yl-amine results in decreased expression of SNAI2 mRNA]	29108245
C121479	2,4-dihydroxybenzophenone	2,4-dihydroxybenzophenone results in increased expression of SNAI2 protein	27145024
C121479	2,4-dihydroxybenzophenone	Fulvestrant inhibits the reaction [2,4-dihydroxybenzophenone results in increased expression of SNAI2 protein]	27145024
C519132	2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride	2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of SNAI2 protein]	22869556
C040668	2-ethylhexanoic acid	2-ethylhexanoic acid results in decreased expression of SNAI2 mRNA	30578912
C034017	2-ethylhexanol	2-ethylhexanol results in increased expression of SNAI2 mRNA	31445079
C016392	3,3'-diindolylmethane	3,3'-diindolylmethane inhibits the reaction [bisphenol A results in increased expression of SNAI2 protein]	28844962
C016392	3,3'-diindolylmethane	3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of SNAI2 protein]	28844962
C016392	3,3'-diindolylmethane	3,3'-diindolylmethane inhibits the reaction [Triclosan results in increased expression of SNAI2 protein]	28844962
C090937	3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole	3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole inhibits the reaction [Oxygen deficiency results in increased expression of SNAI2 protein]	28574600
C041477	3-hydroxyflavone	3-hydroxyflavone results in decreased expression of SNAI2 protein	27600294
C009505	4,4'-diaminodiphenylmethane	4,4'-diaminodiphenylmethane results in decreased expression of SNAI2 mRNA	18648102
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
C016583	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of SNAI2 protein	30236600
C105260	4-tert-octylphenol	4-tert-octylphenol results in increased expression of SNAI2 protein	27145024
C105260	4-tert-octylphenol	Fulvestrant inhibits the reaction [4-tert-octylphenol results in increased expression of SNAI2 protein]	27145024
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of SNAI2 mRNA	20018196; 20382639;
C496492	abrine	abrine results in increased expression of SNAI2 mRNA	31054353
D000082	Acetaminophen	Acetaminophen results in increased expression of SNAI2 mRNA	21420995; 29067470;
D000181	Acrylonitrile	Acrylonitrile results in increased expression of SNAI2 protein	30236600
D016604	Aflatoxin B1	Aflatoxin B1 affects the expression of SNAI2 protein	20106945
D016604	Aflatoxin B1	Aflatoxin B1 results in increased methylation of SNAI2 gene	27153756
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of SNAI2 mRNA	19770486
D000517	alpha-Chlorohydrin	alpha-Chlorohydrin results in increased expression of SNAI2 mRNA	28522335
D000968	Antimycin A	Antimycin A results in increased expression of SNAI2 mRNA	19304788
D016718	Arachidonic Acid	Arachidonic Acid results in increased expression of SNAI2 mRNA	16704987
D000077237	Arsenic Trioxide	Arsenic Trioxide promotes the reaction [Tretinoin results in decreased expression of SNAI2 mRNA]	30093655
D000077237	Arsenic Trioxide	Arsenic Trioxide results in decreased expression of SNAI2 mRNA	25258189; 30093655;
D000077237	Arsenic Trioxide	Arsenic Trioxide results in decreased expression of SNAI2 protein	24680928
D000077237	Arsenic Trioxide	[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of SNAI2 mRNA	29274334
D000077237	Arsenic Trioxide	MIR491 mRNA affects the reaction [Arsenic Trioxide results in decreased expression of SNAI2 protein]	24680928
D000077237	Arsenic Trioxide	Tretinoin promotes the reaction [Arsenic Trioxide results in decreased expression of SNAI2 mRNA]	30093655
C015001	arsenite	[arsenite co-treated with Benzo(a)pyrene] results in decreased expression of SNAI2 mRNA	15894712
C015001	arsenite	arsenite results in decreased expression of SNAI2 mRNA	15894712
C547126	AZM551248	AZM551248 results in increased expression of SNAI2 mRNA	22323515
C487081	belinostat	belinostat results in increased expression of SNAI2 mRNA	26272509
C487081	belinostat	[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of SNAI2 mRNA	27221058; 30659931;
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of SNAI2 protein	30236600
D001564	Benzo(a)pyrene	[arsenite co-treated with Benzo(a)pyrene] results in decreased expression of SNAI2 mRNA	15894712
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of SNAI2 mRNA	15894712; 19770486; 21715664;
C543008	bis(4-hydroxyphenyl)sulfone	bis(4-hydroxyphenyl)sulfone results in increased expression of SNAI2 mRNA	30951980
C006780	bisphenol A	bisphenol A affects the expression of SNAI2 mRNA	21786754; 23557687;
C006780	bisphenol A	3,3'-diindolylmethane inhibits the reaction [bisphenol A results in increased expression of SNAI2 protein]	28844962
C006780	bisphenol A	bisphenol A results in decreased expression of SNAI2 mRNA	29718440
C006780	bisphenol A	bisphenol A results in increased expression of SNAI2 mRNA	25690688; 29275510;
C006780	bisphenol A	bisphenol A results in increased expression of SNAI2 protein	28844962
C006780	bisphenol A	Fulvestrant inhibits the reaction [bisphenol A results in increased expression of SNAI2 mRNA]	25690688
C006780	bisphenol A	Fulvestrant inhibits the reaction [bisphenol A results in increased expression of SNAI2 protein]	28844962
C006780	bisphenol A	plerixafor octahydrochloride inhibits the reaction [bisphenol A results in increased expression of SNAI2 protein]	28844962
C006780	bisphenol A	bisphenol A results in increased expression of SNAI2 mRNA	30951980
C006780	bisphenol A	bisphenol A results in decreased expression of SNAI2 mRNA	25181051; 30816183;
C000611646	bisphenol F	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SNAI2 mRNA	28628672
C000611646	bisphenol F	bisphenol F results in increased expression of SNAI2 mRNA	30951980
C018475	butyraldehyde	butyraldehyde results in increased expression of SNAI2 mRNA	26079696
D002117	Calcitriol	Calcitriol results in increased expression of SNAI2 mRNA	21592394
D002117	Calcitriol	[Testosterone co-treated with Calcitriol] results in increased expression of SNAI2 mRNA	21592394
D002220	Carbamazepine	Carbamazepine affects the expression of SNAI2 mRNA	25979313
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in decreased expression of SNAI2 mRNA	31150632
D007631	Chlordecone	Chlordecone results in decreased expression of SNAI2 mRNA	29458080
C100187	chloropicrin	chloropicrin affects the expression of SNAI2 mRNA	26352163
C100187	chloropicrin	chloropicrin results in decreased expression of SNAI2 mRNA	28476498
D002737	Chloroprene	Chloroprene results in decreased expression of SNAI2 mRNA	23125180
C074702	chromium hexavalent ion	chromium hexavalent ion results in increased expression of SNAI2 mRNA	23518002
C074702	chromium hexavalent ion	chromium hexavalent ion results in increased expression of SNAI2 protein	23518002
C031180	chrysene	chrysene results in increased expression of SNAI2 mRNA	26377693
C043561	chrysin	chrysin results in decreased expression of SNAI2 protein	24122885
D002939	Ciprofloxacin	Ciprofloxacin results in decreased expression of SNAI2 protein	26947806
D002945	Cisplatin	Cisplatin results in increased expression of SNAI2 mRNA	19561079; 21618587;
D002945	Cisplatin	U 0126 inhibits the reaction [Cisplatin results in increased expression of SNAI2 mRNA]	21618587
D003474	Curcumin	Curcumin results in decreased expression of SNAI2 protein	19573523
D016572	Cyclosporine	Cyclosporine results in decreased expression of SNAI2 mRNA	27989131
D016572	Cyclosporine	Cyclosporine results in increased expression of SNAI2 mRNA	20106945
D016572	Cyclosporine	Cyclosporine results in increased expression of SNAI2 mRNA	22416070
D016572	Cyclosporine	Cyclosporine results in increased expression of SNAI2 protein	22416070
D003561	Cytarabine	Cytarabine results in decreased expression of SNAI2 mRNA	21198554
D000077209	Decitabine	Decitabine results in decreased expression of SNAI2 mRNA	30125549
D000077209	Decitabine	Decitabine results in decreased expression of SNAI2 protein	30125549
C017185	delphinidin	delphinidin results in decreased expression of SNAI2 protein	29451351
C040424	destruxin B	destruxin B promotes the reaction [Sorafenib results in decreased expression of SNAI2 protein]	24434019
C040424	destruxin B	destruxin B results in decreased expression of SNAI2 protein	24434019
C040424	destruxin B	Sorafenib promotes the reaction [destruxin B results in decreased expression of SNAI2 protein]	24434019
D003907	Dexamethasone	Dexamethasone results in decreased expression of SNAI2 mRNA	28453788
D003907	Dexamethasone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SNAI2 mRNA	28628672
C042577	diallyl trisulfide	diallyl trisulfide inhibits the reaction [Oxygen deficiency results in increased expression of SNAI2 protein]	28574600
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of SNAI2 mRNA	21266533
C026398	dictamnine	dictamnine inhibits the reaction [Oxygen deficiency results in increased expression of SNAI2 protein]	30266538
C026398	dictamnine	dictamnine promotes the reaction [SNAI2 protein affects the expression of CDH1 mRNA]	30266538
C026398	dictamnine	dictamnine promotes the reaction [SNAI2 protein affects the expression of CDH1 protein]	30266538
C026398	dictamnine	dictamnine promotes the reaction [SNAI2 protein affects the expression of CDH2 mRNA]	30266538
C026398	dictamnine	dictamnine promotes the reaction [SNAI2 protein affects the expression of CDH2 protein]	30266538
C026398	dictamnine	dictamnine promotes the reaction [SNAI2 protein affects the expression of OCLN mRNA]	30266538
C026398	dictamnine	dictamnine promotes the reaction [SNAI2 protein affects the expression of OCLN protein]	30266538
C026398	dictamnine	dictamnine promotes the reaction [SNAI2 protein affects the expression of VIM mRNA]	30266538
C026398	dictamnine	dictamnine promotes the reaction [SNAI2 protein affects the expression of VIM protein]	30266538
C026398	dictamnine	dictamnine results in decreased expression of SNAI2 protein	30266538
C036042	dicyclohexyl phthalate	dicyclohexyl phthalate affects the expression of SNAI2 mRNA	26924002
D004041	Dietary Fats	Dietary Fats results in increased expression of SNAI2 mRNA	18042831
D013196	Dihydrotestosterone	Dihydrotestosterone results in increased expression of SNAI2 mRNA	16541421; 29581250;
C516138	dorsomorphin	[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
D004317	Doxorubicin	Doxorubicin results in decreased expression of SNAI2 mRNA	29803840
C010945	embelin	embelin results in decreased expression of SNAI2 protein	24694877
D004726	Endosulfan	Endosulfan affects the localization of SNAI2 protein	22677888
D004726	Endosulfan	Endosulfan results in increased expression of SNAI2 mRNA	22677888
D004726	Endosulfan	Endosulfan results in decreased expression of SNAI2 mRNA	29391264
C118739	entinostat	entinostat results in increased expression of SNAI2 mRNA	29845424
D000069347	Erlotinib Hydrochloride	[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of SNAI2 mRNA	29274334
D004958	Estradiol	Estradiol affects the expression of SNAI2 mRNA	23557687
D004958	Estradiol	3,3'-diindolylmethane inhibits the reaction [Estradiol results in increased expression of SNAI2 protein]	28844962
D004958	Estradiol	Estradiol affects the expression of SNAI2 mRNA	22574217
D004958	Estradiol	[Estradiol co-treated with TGFB1 protein] results in increased expression of SNAI2 mRNA	30165855
D004958	Estradiol	Estradiol results in decreased expression of SNAI2 protein	15955695
D004958	Estradiol	Estradiol results in increased expression of SNAI2 mRNA	25690688
D004958	Estradiol	Estradiol results in increased expression of SNAI2 protein	28844962
D004958	Estradiol	Fulvestrant inhibits the reaction [Estradiol results in increased expression of SNAI2 mRNA]	25690688
D004958	Estradiol	Fulvestrant inhibits the reaction [Estradiol results in increased expression of SNAI2 protein]	28844962
D004958	Estradiol	plerixafor octahydrochloride inhibits the reaction [Estradiol results in increased expression of SNAI2 protein]	28844962
D000431	Ethanol	Ethanol results in decreased expression of SNAI2 mRNA	28919490
C007738	fluoranthene	[1-methylanthracene co-treated with fluoranthene] results in increased expression of SNAI2 mRNA	28329830
D005472	Fluorouracil	Fluorouracil results in increased expression of SNAI2 protein	26310874
D005472	Fluorouracil	Resveratrol inhibits the reaction [Fluorouracil results in increased expression of SNAI2 protein]	26310874
D005557	Formaldehyde	Formaldehyde results in decreased expression of SNAI2 mRNA	28937961
D005557	Formaldehyde	Formaldehyde results in increased expression of SNAI2 protein	30236600
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [2,4-dihydroxybenzophenone results in increased expression of SNAI2 protein]	27145024
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [4-tert-octylphenol results in increased expression of SNAI2 protein]	27145024
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [bisphenol A results in increased expression of SNAI2 mRNA]	25690688
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [bisphenol A results in increased expression of SNAI2 protein]	28844962
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [Estradiol results in increased expression of SNAI2 mRNA]	25690688
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [Estradiol results in increased expression of SNAI2 protein]	28844962
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [nonylphenol results in increased expression of SNAI2 mRNA]	25690688
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [Triclosan results in increased expression of SNAI2 protein]	28844962
D005742	Gasoline	[[Gasoline co-treated with 1-Butanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SNAI2 mRNA	29432896
D000077156	Gefitinib	SNAI2 protein affects the susceptibility to Gefitinib	21037017
C055124	glaucocalyxin A	glaucocalyxin A inhibits the reaction [TGFB1 protein results in increased expression of SNAI2 mRNA]	31059706
C055124	glaucocalyxin A	glaucocalyxin A inhibits the reaction [TGFB1 protein results in increased expression of SNAI2 protein]	31059706
C055124	glaucocalyxin A	glaucocalyxin A results in increased expression of SNAI2 mRNA	31059706
C055124	glaucocalyxin A	glaucocalyxin A results in increased expression of SNAI2 protein	31059706
D001556	Hexachlorocyclohexane	Hexachlorocyclohexane affects the expression of SNAI2 mRNA	17785943
D006820	Hyaluronic Acid	Hyaluronic Acid analog results in increased expression of SNAI2 mRNA	20159036
D006820	Hyaluronic Acid	Hyaluronic Acid analog results in increased expression of SNAI2 protein	20159036
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in increased expression of SNAI2 protein	22580338
D007213	Indomethacin	Indomethacin results in increased expression of SNAI2 mRNA	16984733
D007213	Indomethacin	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SNAI2 mRNA	28628672
C005059	isoprene	isoprene results in increased expression of SNAI2 protein	30236600
C544151	jinfukang	jinfukang results in increased expression of SNAI2 mRNA	27392435
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of SNAI2 mRNA	24796395
D019344	Lactic Acid	Lactic Acid results in increased expression of SNAI2 mRNA	30851411
D000077339	Leflunomide	Leflunomide results in increased expression of SNAI2 mRNA	28988120
D058185	Magnetite Nanoparticles	[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of SNAI2 mRNA	26378955
C013592	mangiferin	mangiferin results in decreased expression of SNAI2 protein	23707762
C042720	mercuric bromide	mercuric bromide results in increased expression of SNAI2 mRNA	26272509
C042720	mercuric bromide	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
D008687	Metformin	Metformin results in increased expression of SNAI2 mRNA	31324951
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of SNAI2 mRNA	26272509; 28001369;
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in decreased expression of SNAI2 mRNA	26011545
D008770	Methylnitrosourea	Methylnitrosourea results in decreased expression of SNAI2 mRNA	27221058
D008770	Methylnitrosourea	[Methylnitrosourea co-treated with Testosterone] results in increased expression of SNAI2 mRNA	25164625
D008770	Methylnitrosourea	Quercetin inhibits the reaction [[Methylnitrosourea co-treated with Testosterone] results in increased expression of SNAI2 mRNA]	25164625
C008493	methylselenic acid	methylselenic acid results in increased expression of SNAI2 mRNA	18548127
C043243	methyl tert-butyl ether	methyl tert-butyl ether affects the expression of SNAI2 mRNA	24128854
C548887	MK 2206	[U 0126 co-treated with MK 2206] results in decreased expression of SNAI2 mRNA	30723155
C517284	monomethyl phthalate	monomethyl phthalate affects the expression of SNAI2 mRNA	26924002
D037742	Nanotubes, Carbon	Nanotubes, Carbon analog results in decreased expression of SNAI2 mRNA	25554681
D037742	Nanotubes, Carbon	Nanotubes, Carbon results in decreased expression of SNAI2 mRNA	25554681
C005273	naringenin	naringenin results in decreased expression of SNAI2 protein	30431227
C022838	nickel chloride	nickel chloride promotes the reaction [SNAI2 protein binds to CDH1 promoter]	22648416
C022838	nickel chloride	nickel chloride results in increased expression of SNAI2 protein	22648416
D009534	Niclosamide	Niclosamide results in decreased expression of SNAI2 mRNA	31398420
D009534	Niclosamide	Niclosamide results in decreased expression of SNAI2 protein	25174399
D009534	Niclosamide	WNT7A protein affects the reaction [Niclosamide results in increased expression of SNAI2 protein]	25174399
D009538	Nicotine	Nicotine results in increased expression of SNAI2 mRNA	23219715
D009538	Nicotine	Nicotine results in decreased expression of SNAI2 mRNA	20339300
C000623013	NMS-873	NMS-873 results in decreased expression of SNAI2 protein	29693262
C025256	nonylphenol	Fulvestrant inhibits the reaction [nonylphenol results in increased expression of SNAI2 mRNA]	25690688
C025256	nonylphenol	nonylphenol results in increased expression of SNAI2 mRNA	25690688
C570897	NSC668394	NSC668394 results in increased expression of SNAI2 mRNA	27137931
C011959	oridonin	oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI2 mRNA]	30243739
C011959	oridonin	oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI2 protein]	30243739
C011959	oridonin	oridonin results in decreased expression of SNAI2 mRNA	30243739
C011959	oridonin	oridonin results in decreased expression of SNAI2 protein	30243739
D010100	Oxygen	3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole inhibits the reaction [Oxygen deficiency results in increased expression of SNAI2 protein]	28574600
D010100	Oxygen	diallyl trisulfide inhibits the reaction [Oxygen deficiency results in increased expression of SNAI2 protein]	28574600
D010100	Oxygen	dictamnine inhibits the reaction [Oxygen deficiency results in increased expression of SNAI2 protein]	30266538
D010100	Oxygen	Oxygen deficiency results in increased expression of SNAI2 protein	28574600; 30266538;
D010100	Oxygen	[NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of SNAI2 mRNA	30529165
C500026	palbociclib	2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of SNAI2 protein]	22869556
C500026	palbociclib	palbociclib results in increased expression of SNAI2 protein	22869556
D000073878	Palm Oil	Palm Oil results in increased expression of SNAI2 mRNA	18042831
D000077767	Panobinostat	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
D000077767	Panobinostat	Panobinostat results in increased expression of SNAI2 mRNA	26272509
D052638	Particulate Matter	[[Gasoline co-treated with 1-Butanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SNAI2 mRNA	29432896
C568608	PCI 5002	[PCI 5002 co-treated with Zinc] results in increased expression of SNAI2 mRNA	18593933
D010416	Pentachlorophenol	Pentachlorophenol results in increased expression of SNAI2 mRNA	24642059
D010426	Pentosan Sulfuric Polyester	Pentosan Sulfuric Polyester results in decreased expression of SNAI2 mRNA	28973697
D010629	Phenformin	Phenformin results in increased expression of SNAI2 mRNA	31324951
D010634	Phenobarbital	Phenobarbital affects the expression of SNAI2 mRNA	19159669
D010634	Phenobarbital	Phenobarbital results in decreased expression of SNAI2 mRNA	23091169
D010662	Phenylmercuric Acetate	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in increased expression of SNAI2 mRNA	26272509
D010936	Plant Extracts	Plant Extracts results in decreased expression of SNAI2 mRNA	23557933
C088327	plerixafor octahydrochloride	plerixafor octahydrochloride inhibits the reaction [bisphenol A results in increased expression of SNAI2 protein]	28844962
C088327	plerixafor octahydrochloride	plerixafor octahydrochloride inhibits the reaction [Estradiol results in increased expression of SNAI2 protein]	28844962
C088327	plerixafor octahydrochloride	plerixafor octahydrochloride inhibits the reaction [Triclosan results in increased expression of SNAI2 protein]	28844962
D011084	Polycyclic Aromatic Hydrocarbons	[[Gasoline co-treated with 1-Butanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of SNAI2 mRNA	29432896
C060540	polyhexamethyleneguanidine	polyhexamethyleneguanidine results in increased expression of SNAI2 mRNA	31348943
D011374	Progesterone	Progesterone results in decreased expression of SNAI2 mRNA	23012394; 23018184;
D011794	Quercetin	Quercetin inhibits the reaction [[Methylnitrosourea co-treated with Testosterone] results in increased expression of SNAI2 mRNA]	25164625
C012526	quercitrin	quercitrin affects the expression of SNAI2 mRNA	25193878
D000077185	Resveratrol	Resveratrol inhibits the reaction [Fluorouracil results in increased expression of SNAI2 protein]	26310874
D000077185	Resveratrol	Resveratrol inhibits the reaction [TGFB1 protein results in increased expression of SNAI2 mRNA]	23146760
D000077185	Resveratrol	Resveratrol inhibits the reaction [TGFB1 protein results in increased expression of SNAI2 protein]	23146760; 25884904;
D000077185	Resveratrol	Resveratrol results in decreased expression of SNAI2 mRNA	21304978; 22692956;
D000077185	Resveratrol	Resveratrol results in decreased expression of SNAI2 protein	22692956; 26310874;
C009166	retinol acetate	retinol acetate results in increased expression of SNAI2 mRNA	16772331
D012402	Rotenone	Rotenone results in increased expression of SNAI2 mRNA	19304788
D012715	Sesame Oil	Sesame Oil results in increased expression of SNAI2 mRNA	29191790
C017947	sodium arsenite	sodium arsenite deficiency inhibits the reaction [sodium arsenite results in increased expression of SNAI2 protein]	28336213
C017947	sodium arsenite	sodium arsenite results in increased expression of SNAI2 mRNA	31120745
C017947	sodium arsenite	sodium arsenite results in increased expression of SNAI2 protein	28336213
D000077157	Sorafenib	destruxin B promotes the reaction [Sorafenib results in decreased expression of SNAI2 protein]	24434019
D000077157	Sorafenib	Sorafenib promotes the reaction [destruxin B results in decreased expression of SNAI2 protein]	24434019
D000077157	Sorafenib	Sorafenib results in decreased expression of SNAI2 protein	24434019
D004113	Succimer	[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of SNAI2 mRNA	26378955
D016559	Tacrolimus	Tacrolimus results in increased expression of SNAI2 mRNA	22416070
D020122	tert-Butylhydroperoxide	tert-Butylhydroperoxide results in increased expression of SNAI2 mRNA	15336504
D013739	Testosterone	[Testosterone co-treated with Calcitriol] results in increased expression of SNAI2 mRNA	21592394
D013739	Testosterone	Testosterone results in increased expression of SNAI2 mRNA	21592394
D013739	Testosterone	[Methylnitrosourea co-treated with Testosterone] results in increased expression of SNAI2 mRNA	25164625
D013739	Testosterone	Quercetin inhibits the reaction [[Methylnitrosourea co-treated with Testosterone] results in increased expression of SNAI2 mRNA]	25164625
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of SNAI2 mRNA	16443690
D013749	Tetrachlorodibenzodioxin	AHR protein affects the reaction [Tetrachlorodibenzodioxin results in increased expression of SNAI2 mRNA]	26971374
D013749	Tetrachlorodibenzodioxin	AHR protein affects the reaction [Tetrachlorodibenzodioxin results in increased expression of SNAI2 protein]	26971374
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to SNAI2 promoter]	24154488; 26971374;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to SNAI2 protein]	26971374
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of SNAI2 mRNA	20106945; 21632981; 24154488; 26971374;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of SNAI2 protein	24154488; 26971374;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of SNAI2 mRNA	26377647
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of SNAI2 mRNA	19770486; 19933214;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of SNAI2 mRNA	17586704; 24154488;
D013853	Thioacetamide	Thioacetamide results in decreased expression of SNAI2 mRNA	23411599
D013893	Thiram	Thiram results in increased expression of SNAI2 mRNA	20530235
C009495	titanium dioxide	titanium dioxide results in decreased expression of SNAI2 mRNA	23557971; 29264374;
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of SNAI2 protein	27087172
D014212	Tretinoin	Tretinoin results in decreased expression of SNAI2 mRNA	20530235
D014212	Tretinoin	Arsenic Trioxide promotes the reaction [Tretinoin results in decreased expression of SNAI2 mRNA]	30093655
D014212	Tretinoin	Tretinoin promotes the reaction [Arsenic Trioxide results in decreased expression of SNAI2 mRNA]	30093655
D014212	Tretinoin	Tretinoin results in decreased expression of SNAI2 mRNA	21934132; 30093655;
D014212	Tretinoin	Tretinoin results in increased expression of SNAI2 mRNA	23724009
D014212	Tretinoin	Tretinoin results in increased expression of SNAI2 mRNA	17038669
C034613	triacsin C	triacsin C results in increased expression of SNAI2 mRNA	16704987
C011559	tributyltin	tributyltin results in decreased expression of SNAI2 mRNA	29505797
C012589	trichostatin A	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
C012589	trichostatin A	trichostatin A results in increased expression of SNAI2 mRNA	24935251; 26272509;
D014260	Triclosan	3,3'-diindolylmethane inhibits the reaction [Triclosan results in increased expression of SNAI2 protein]	28844962
D014260	Triclosan	Fulvestrant inhibits the reaction [Triclosan results in increased expression of SNAI2 protein]	28844962
D014260	Triclosan	plerixafor octahydrochloride inhibits the reaction [Triclosan results in increased expression of SNAI2 protein]	28844962
D014260	Triclosan	Triclosan results in increased expression of SNAI2 protein	28844962
C016805	tris(1,3-dichloro-2-propyl)phosphate	tris(1,3-dichloro-2-propyl)phosphate results in increased expression of SNAI2 mRNA	26743178
D000077288	Troglitazone	Troglitazone results in decreased expression of SNAI2 mRNA	28973697
C113580	U 0126	U 0126 inhibits the reaction [Cisplatin results in increased expression of SNAI2 mRNA]	21618587
C113580	U 0126	[U 0126 co-treated with MK 2206] results in decreased expression of SNAI2 mRNA	30723155
C113580	U 0126	U 0126 results in decreased expression of SNAI2 mRNA	30723155
D014520	Urethane	Urethane results in increased expression of SNAI2 mRNA	28818685
D014635	Valproic Acid	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
D014635	Valproic Acid	Valproic Acid affects the expression of SNAI2 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of SNAI2 mRNA	23179753
D014635	Valproic Acid	Valproic Acid results in increased expression of SNAI2 mRNA	23179753; 24383497; 24935251; 26272509;
D014635	Valproic Acid	Valproic Acid results in decreased expression of SNAI2 mRNA	30578912
D014635	Valproic Acid	Valproic Acid results in increased expression of SNAI2 mRNA	24896083; 31445079;
D014638	Vanadates	Vanadates results in increased expression of SNAI2 mRNA	22714537
D001335	Vehicle Emissions	Vehicle Emissions affects the methylation of SNAI2 gene	25560391
C025643	vinclozolin	vinclozolin results in decreased expression of SNAI2 mRNA	21126777
D000077337	Vorinostat	[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA	27188386
D000077337	Vorinostat	Vorinostat results in increased expression of SNAI2 mRNA	26272509
D014859	Warfarin	SNAI2 protein promotes the reaction [TP53 protein results in increased susceptibility to Warfarin]	29358327
D014859	Warfarin	SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA]	29358327
D014859	Warfarin	SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA]	29358327
D014859	Warfarin	SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein]	29358327
D014859	Warfarin	[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of SNAI2 protein	29358327
D014859	Warfarin	Warfarin promotes the reaction [TP53 protein binds to SNAI2 promoter]	29358327
D015025	Zearalenone	Zearalenone results in decreased expression of SNAI2 mRNA	28965971
D015032	Zinc	[PCI 5002 co-treated with Zinc] results in increased expression of SNAI2 mRNA	18593933
D015032	Zinc	Zinc binds to SNAI2 protein	18761175

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0963	Cytoplasm
KW-0209	Deafness
KW-0217	Developmental protein
KW-0238	DNA-binding
KW-0479	Metal-binding
KW-0539	Nucleus
KW-0621	Polymorphism
KW-1185	Reference proteome
KW-0677	Repeat
KW-0678	Repressor
KW-0804	Transcription
KW-0805	Transcription regulation
KW-0897	Waardenburg syndrome
KW-0862	Zinc
KW-0863	Zinc-finger

Interpro

InterPro ID	InterPro Term
IPR036236	Znf_C2H2_sf
IPR013087	Znf_C2H2_type

PROSITE

PROSITE ID	PROSITE Term
PS00028	ZINC_FINGER_C2H2_1
PS50157	ZINC_FINGER_C2H2_2

Pfam

Pfam ID	Pfam Term
PF00096	zf-C2H2

Gene: SNAI2

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

There is no related protein structure for this gene.

Protein disorder information

Orthologous information

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction